CZ309222B6 - Nutritional food supplement containing granulated colostrum - Google Patents

Abstract

The invention provides a nutritional supplement comprising an enteric coating and a core comprising colostrum and a filler. The nutritional supplement contains un-ground granular colostrum of 10% by weight to 30% by weight, filler of from 60% by weight to 80% by weight and an enteric coating of from 2% by weight to 6% by weight in view of 100% by weight of the composition. The colostrum is goat and / or cow colostrum, the minimum content of immunoglobulin fraction in the colostrum is 21% by weight in view of the weight of the colostrum. The invention includes a method of making the dietary supplement comprising removing colostrum from a female animal no later than 6 hours postpartum, cooling it to at least 4 °C and freezing it to at least -25 °C, drying the colostrum by lyophilization or spray drying, sieving the lyophilized colostrum through a sieve to form a granulate, homogenizing the colostrum granulate with a filler, pressing the homogenized mixture into a core, and applying an aqueous enteric coating solution.

Description

Nutritional food supplement containing granulated colostrum

Field of technology

The invention relates to a nutritional food supplement containing granulated colostrum, especially goat and cow colostrum obtained in the first 6 hours after birth, with supporting properties for the immune system.

Current state of the art

Colostrum, otherwise called colostrum, is a form of milk produced by the mammary gland of mammals during pregnancy. Colostrum contains protein antibodies to protect the newborn or young from diseases. In general, the concentration of these proteins in colostrum is significantly higher than in milk. Colostrum, which is rich in IGF-I protein, also contains antioxidant components such as lactoferrin and hemopexin, which bind free heme in the body. Colostrum also contains casein, glycomacropeptides, a complex of linolenic and oleic acids, lysozyme responsible for the lysis of weakened bacterial cells, immunoglobulins IgG, IgM, IgA, IgD, IgE, vitamins, minerals, especially calcium, phosphorus and potassium, and natural growth factors IGF-II, EGF, TGF-A, TGF-B.

The proteins contained in colostrum are rich in proline and are responsible for controlling the production of specific proteins. These small immune signaling peptides (PRPs) have been independently discovered in colostrum and other sources such as blood plasma. Therefore, they appear in the literature under different names, including colostrinin, CLN, transfer factor, and PRP. They act as signal transduction molecules that have the unique effect of modulating the immune system, turning it on when the body is attacked by pathogens, for example, and shutting it down when danger is eliminated or neutralized. Colostrum production stops just after birth. Labor signals the body to start producing breast milk. After the first feeding, colostrum gradually begins to change into milk. This period lasts 2 to 3 days, and such a liquid is called transitional milk. In all mammals, colostrum is important for the survival of the newborn. The reason is the high concentration of immune factors that colostrum contains.

Nutritional supplement made from dried goat colostrum to support immunity and the method of its production is described in the Czech utility model CZ 24712 Ul. The nutritional supplement for the support of immunity contains at least 30% mass, dried goat colostrum and is in the form of natural capsules or powder. Milked goat colostrum is quickly cooled immediately after milking and frozen in a special quick-freeze box and dried by lyophilization at temperatures of -50 to -60 °C, or dried in a spray dryer at a temperature drop of 160 °C to 60 °C. Goat colostrum is collected within 24 hours of the birth of the kid. The disadvantage is the gradual decrease in the content of the immunoglobulin fraction during the first 24 hours after birth. The disadvantage of the powdered form of colostrum is the need for an additional processing step of the lyophilized granulate, as well as contact with metal parts of the grinding device, which can cause the deactivation of some colostrum components, e.g. coenzyme Q10, lysozyme of atelomerase.

The Czech utility model CZ 30057 Ul describes a mixture of 40 to 80% mass, dried cow colostrum, 10 to 40% mass, prebiotics, 5 to 15% mass, lyophilized mixture of probiotic lactic acid bacteria and bifidobacteria and 5 to 15% mass, mineral substances in capsule form.

Milk or a milk product based on cow's, goat's, sheep's, buffalo's or mare's milk is described in the Slovak invention application SK 50147-2014. The essence of any of the product groups is that milk or milk products, for example drinking milk, drinking creams, modified milk and modified milk products, flavored milk and flavored liquid milk products, sour milk products - fermented milk products, condensed milk products, dry milk , milk proteins including caseinates, cheeses, butter and other milk fats or buttermilk contain 0.01 to 45% by volume of colostrum based on the total mixture. Cow's, goat's, sheep's, buffalo's or mare's milk or their mixture can be used to make these products.

-1 CZ 309222 B6

The method of producing yogurt from colostrum is described in the Chinese application CN 102488005 A. The method of producing yogurt with colostrum includes the following steps, where first 20 to 100 parts by weight of white sugar and 4.5 parts by weight of stabilizer are added to 700 parts by weight of raw milk, followed by homogenization . Following homogenization, 200 parts by weight of colostrum are added to the mixture for sterilization and the mixture is inoculated with 0.02 parts by weight of bifidobacteria. Finally, 0.01 to 0.02 parts by weight of aromatic essence is added to the mixture, followed by fermentation to obtain colostrum yogurt.

A dietary supplement containing a colostrum component composed of processed bovine colostrum, magnesium peroxide as a source of active oxygen, a vitamin such as vitamin C, magnesium succinate, and a bioflavonoid is described in US Patent 5,846,569 A. This dietary supplement can be mixed with other minerals, vitamins, and similarly. In one form, the colostrum component is used as an outer shell for a composite pill, tablet, or capsule that contains an inner core containing one or more vitamins, minerals, enzymes, or omega-acids in the event that the components of the inner core are incompatible with one or more of the component materials colostrum. In this way, a large number of supplements can be provided that offer the benefits of colostrum and active oxygen and the benefits of other materials that can be taken as a single pill or capsule.

In the Chinese patent application CN 106376649 A, a tablet is described which is supposed to strengthen immunity. The tablet contains the following ingredients by weight: 8 to 12 parts bovine colostrum powder, 0.8 to 2 parts taurine, 1.8 to 3.3 parts skimmed milk powder, 4 to 6.5 parts glucose and 0.1 to 0, 27 parts of magnesium stearate.

The disadvantages of tablets with colostrum, which describes the state of the art, mainly consist in the fact that they contain a large amount of substances that are necessary to achieve the correct mechanical properties of the tablet.

Other disadvantages of the above state of the art are that when tablets, capsules or powders containing colostrum are taken orally by an adult or a child, the colostrum components pass through the digestive tract, where their structures are degraded by means of the acidic pH in the stomach and digestive enzymes produced by the digestive glands of the digestive tract . Only their non-functional modifications subsequently reach the blood. This applies especially to the protein components contained in colostrum, whose biological properties are strictly conditioned by their structure.

Enteric coating compositions based on acrylates, methacrylates and their esters are described, for example, in the international patent application WO 01/58429 A1 or in the Czech patent CZ 282760 B6.

International patent application WO 95/08562 A1 describes a pharmaceutical composition in the form of a tablet containing a core with active antibodies obtained mainly from colostrum. The compression force for the preparation of tablets is set so as not to damage the active antibodies contained in the composition. The tablet core can be coated with an enteric coating for targeted release of active substances from the tablet core in the digestive tract. The enteric coating can be based on an enteric polymer, which is sold under the trade name Eudragit® L 100-55. The 500 mg tablet core contains 80% antibodies, 6% microcrystalline cellulose, 3.2% carboxymethylcellulose, 6% citric acid, 6% sodium bicarbonate and 0.8% magnesium stearate. The enteric coating of the tablet is prepared by dispersing Eudragit L 100-55 with 3% acetyl alcohol and the resulting mixture is sprayed evenly onto the surface of the tablet core. Sufficient enteric coating on the surface of the tablet core is produced when 2 to 5% enteric suspension is used. The disadvantage of the above-mentioned pharmaceutical composition lies mainly in the complex preparation of highly pure and active antibodies from goat colostrum.

European patent EP 0725789 B1 describes a tablet comprising a core and an enteric coating, wherein the core comprises an active antibody component obtained from colostrum, and optionally also magnesium stearate, silicon dioxide and/or microcrystalline cellulose, and the enteric coating comprises, for example, a copolymer of methacrylates and ethyl- acrylate (1:1). Colostrum is obtained in the first 2 days after birth

-2 CZ 309222 B6 and further processed (removal of fat, pasteurization, coagulation, removal of casein, centrifugation, removal of lactose, minerals and water, dialysis of the immunoglobulin fraction in Tris-HCl buffer and concentration). The disadvantage of the mentioned active antibody component is the absence of other proteins in the colostrum after processing and the collection of colostrum only in the first 48 hours after birth, which results in a lower content of the immunoglobulin fraction.

German patent application DE 102007050574 A1 describes a tablet comprising colostrum with an immunoglobulin content of min. 6% mass (preferably min. 20% mass), glucan (e.g. betaglucan), sugar alcohol (e.g. sorbitol, isomaltitol, maltitol, xylitol), magnesium stearate, microcrystalline cellulose and other additives. Colostrum collected within 12 hours p.p., e.g. from the first or second milking. The disadvantage of the mentioned tablets is the content of excess sugar alcohols, which can affect the absorbability of the protein components of colostrum in the digestive tract. Since the tablet does not include an enteric coating, its digestion will already occur in the acidic environment of the stomach, which has a negative effect on the absorbability of colostrum proteins in their active form.

From the German utility model DE 202008011423 Ul, a combination of natural and gastro-resistant (enteric) form of colostrum granulate is known. Colostrum can be stripped of casein and fat, and a granulate is made by lyophilization or spray drying. Capsule, gel, tablet, lozenge and liquid mixture dosage forms are mentioned. It is not clear how the gastro-resistant properties of colostrum are achieved. In addition, colostrum is collected during the first 24 hours after birth, which reduces the content of the immunoglobulin fraction in colostrum.

German utility model DE 202008011424 Ul describes gastro-resistant colostrum in granular form obtained by lyophilization and with an enteric coating. The disadvantage is a similarly lower share of the immunoglobulin fraction in colostrum collected during the first 24 hours after birth.

International patent application WO 03/041512 A1 describes a nutritional food supplement containing an enteric coating and a core containing colostrum and a filler, whereby the nutritional food supplement contains colostrum in liquid, powder or freeze-dried form in an amount from 1% mass to 40% mass. , filler in the form of the sum of prebiotic (inulin), probiotic and carrier in an amount from 1.1% mass to 65% mass, and an enteric coating in an amount from 4.8% mass, relative to 100% of the weight of the nutritional supplement. Colostrum can be goat, sheep and/or cow colostrum. The minimum declared content of the immunoglobulin fraction (IgG) in colostrum is 15% mass, relative to the weight of colostrum. The disadvantage of this nutritional supplement is the low declared IgG content in colostrum and the powdered form of colostrum.

American patent US 5780028 A describes a method of obtaining immunoglobulins from colostrum and their use in a pharmaceutical composition. The colostrum is defatted, pasteurized, precipitated with (NELOVE (casein removal), centrifuged, lactose, minerals, and water are removed (by reverse osmosis or ultrafiltration), and the antibody fraction is dissolved in TRIS-HC1 buffer, dialyzed, concentrated, and lyophilized. Lyophilized Antibody Fraction is subsequently compressed into a tablet core containing 20 to 90% by weight, preferably 40 to 80% by weight, and optionally with other active substances (medicines) or fillers (microcrystalline cellulose, aerosil). The tablet core is coated with an enteric coating, especially EUDRAGIT L 100-55 (copolymer poly(methacrylic acid-Lo-ethyl acrylate) 1:1) appears to be preferred. In one exemplary embodiment, the content of the antibody fraction of colostrum is 80% by weight, microcrystalline cellulose 6% by weight, and EUDRAGIT L 100-55 2 to 5% mass. The disadvantage of this method and pharmaceutical composition is the use of a purified antibody fraction of colostrum without other beneficial substances contained in it, especially without fat, microbiota, casein u, lactose, minerals and water.

Two articles were also published, namely E. Haas: "Colostrum, mother nature's strong choice - and why it's worth to follow" (24.6.2019) and P. Chavette: "Field Determination of Colostrum Quality Using a Novel, Practical Method" ( 11/1998). The first of them describes a concentration of > 50 g/1 IgG in powdered colostrum collected within 6 h after birth. Furthermore, standardized IgG contents in first-day colostrum are described as 15, 20 or 30%. The last two listed contents (20 and 30%) are

-3 CZ 309222 B6, however, only after centrifugation of the colostrum, whereby only the first of the listed contents (15%) of the colostrum is obtained without centrifugation. A concentration of 50 g/1 IgG in liquid form corresponds to approximately 5% mass. IgG, from which a standardized content of approximately 15% IgG can be obtained in powdered colostrum. The second article describes the method of determining the concentration of colostrum by refractometry, whereby a concentration > 60 g/1 IgG corresponds to colostrum collected within 6 h after birth and an IgG content in liquid form of approximately 6% by mass, from which a standardized content of approximately 18% IgG in powdered colostrum can be obtained . The alcohol refractometer gives the value of this limit as 16°, and the sugar refractometer gives this value as 23% sugar. The disadvantage of these compositions is the low declared IgG content in non-centrifuged colostrum.

The essence of the invention

The aim of the invention is to propose a nutritional food supplement containing colostrum in a granulated, unground form to support immunity with the help of a minimum amount of auxiliary substances. And to increase efficiency, colostrum can be provided with an enteric coating, which results in improved transport of individual components of colostrum, especially the protein component, into the bloodstream in their unchanged and biologically active form.

The above-mentioned goal has been achieved and the object of this invention is a nutritional food supplement comprising an enteric coating and a core containing colostrum and a filler, the essence of which is that it contains colostrum in granulated, unground form in an amount from 10% mass to 30% mass. filler in an amount from 60% by weight to 80% by weight, and enteric coating in an amount from 2% by weight to 6% by weight, relative to 100% by weight of the composition. The colostrum is goat and/or cow colostrum and the minimum content of the immunoglobulin fraction in the colostrum is 21% by mass, relative to the weight of the colostrum.

Colostrum is preferably provided in a granular, unground form that does not come into contact with grinding equipment (usually stainless steel surfaces). The advantage of granulate (so-called granular powder) compared to powder form is simpler processing without the step of grinding the granulate (lyophilisate) into a powder with finer particles. During the grinding process, the granulate comes into contact with the stainless steel surfaces of the grinding device, which negatively affects the content of active substances in colostrum, e.g. coenzyme Q10, lysozyme or telomerase.

An important aspect of this invention is the content of colostrum in granulated, unground form in an amount from 10% mass to 30% mass. At a content higher than 30% by mass, a problem arises when pressing the homogenized mixture into the core of the pharmaceutical form (e.g. tablets), which falls out of the press with difficulty. With a content lower than 10% mass, there are not enough active substances in the dietary supplement, e.g. immunoglobulin fractions.

An important aspect of this invention is also the content of the filler in an amount from 60% by mass to 80% by mass. The filler in the form of psyllium, inulin and/or microcrystalline cellulose has, in addition to the filling function, also the function of a moisture stabilizer, which is slightly variable in the obtained colostrum. At a content higher than 80% by mass, there will be not only lower contents of active substances, but also excessive absorption of moisture by the filler and swelling, thereby impairing the mechanical properties of the dosage form. At a content lower than 60% mass, on the contrary, there is insufficient absorption of moisture from the colostrum, and the pharmaceutical form (e.g. tablet) disintegrates.

An important aspect of this invention is also the content of the enteric coating in an amount from 2% mass to 6% mass. At a content higher than 6% mass, and also at a content lower than 2% mass, dosage forms (e.g. tablets) crack, break and are unstable.

In order to maintain a minimum content of the immunoglobulin fraction of 21% mass, goat and/or cow colostrum must be collected no later than 6 h after birth, preferably no later than 2 h after the birth of a kid and/or calf.

-4 CZ 309222 B6

The filler can advantageously be psyllium, inulin or microcrystalline cellulose, or a combination thereof. The advantage of psyllium is ensuring better absorbability of colostrum in the digestive tract. The advantage of inulin is its degradability by bacterial enzymes in the microbiome, so inulin is a source of energy for symbiotic intestinal bacteria and also has a probiotic effect.

The enteric coating can advantageously be an anionic copolymer of methacrylate and ethyl acrylate with a ratio of free carboxyl groups to ester groups of 1:1 (e.g. Eudragit L100-55). The enteric coating, which is gradually broken down by the acidic environment in the stomach and digestive enzymes during transport through the digestive tract, ensures the transport of a greater number of colostrum components, especially its protein components, into the bloodstream in their original and biologically active form.

The nutritional food supplement according to the present invention may further include an anti-caking agent to prevent particle agglomeration (e.g. magnesium stearate) in an amount from 0% mass to 1% mass, and a sliding agent to increase flowability, reduce friction and adhesion (e.g. Aerosil, so-called .fumed silica) in an amount from 0% by mass to 2% by mass, relative to 100% by weight of the composition. Excipients are therefore only contained in an amount of a maximum of 3% by mass, relative to 100% by weight of the composition. The ratio of anti-caking and sliding agents was chosen so that, in combination with the enteric coating, it was sufficient to maintain the correct mechanical properties of the packaging (homogeneous structure after pressing, compactness).

According to an advantageous embodiment, the nutritional food supplement based on colostrum and an enteric coating can be in the form of a tablet, capsule, lozenge, dragee or suppository.

The subject of this invention is also a method of producing the mentioned nutritional food supplement, which includes the steps:

a. removal of colostrum from a female animal no later than 6 h after parturition, preferably no later than 2 h after parturition;

b. cooling the colostrum to at least 4 °C and freezing the colostrum to at least -25 °C;

c. drying colostrum by lyophilization or spray drying;

d. sifting lyophilized colostrum through a sieve to form granulate;

e. homogenization of colostrum granulate with filler;

f. pressing the homogenized mixture into the core; and

g. application of an aqueous solution of an enteric coating.

Goat or cow colostrum is produced by a method known from the state of the art, in which the milked goat or cow colostrum is quickly cooled to at least 4 °C immediately after milking and then frozen to at least -25 °C in a quick-freeze box, while observing all hygiene rules. It is then dried by lyophilization at a temperature of around -50 °C or dried in a spray dryer at a temperature drop from 160 °C to 60 °C.

The lyophilized colostrum is sifted through sieves (e.g. with a mesh size of 0.5 to 2 mm) to form a granulate with a particle size of 1 to 3 mm, which is further homogenized with the filler for 20 min at 15 rpm, then the homogenized mixture is pressed into the core at a force of 60 kN, and finally the enteric coating is applied to the core by spraying in a 15% by volume aqueous solution at a volume flow rate of 0.12 1/min for 120 min. The coating system of the enteric packaging is mixed with pure water, which is used as a solvent. After mixing with pure water for 30 minutes, a uniform suspension or solution can be obtained that can be sprayed onto the surface of the tablet core to form

-5 CZ 309222 B6 enteric packaging. In the step of homogenizing the mixture of colostrum granulate and filler, an anti-caking and/or sliding agent can also be added, as described above. After the step of removing and cooling the colostrum to 4°C, the step of removing the casein and lipids from the colostrum by means of membrane filtration can be advantageously followed, thereby obtaining defatted colostrum devoid of the casein component.

The main advantage of a nutritional food supplement comprising an enteric coating and a core containing colostrum in granulated, unground form and a filler is that the colostrum is obtained no later than 6 hours, preferably no later than 2 hours after the birth of the kid, or calf and is processed in a minimum number of processing steps to maintain a high content of the immunoglobulin fraction (21% by weight relative to the weight of colostrum) and with a minimum amount of auxiliary substances (maximum 3% by weight relative to 100% weight of the composition) to ensure correct mechanical properties . Valuable components of colostrum are advantageously delivered to the small intestine, where, thanks to the filler used, better absorption of its protein components in their original and biologically active form occurs, which leads to a higher efficiency of the present invention. In addition, due to the skipping of the step of grinding dried colostrum into powder, the colostrum does not come into contact with the stainless steel surfaces of the grinding device, thereby deactivating some colostrum components, e.g. coenzyme Q10, lysozyme, and atelomerase.

Examples of implementation of the invention

The invention will be explained in more detail using the examples of tablets with different weights of the main component of goat and/or cow colostrum. The examples given in the application of the invention are not limiting for other variants of the invention, which are obvious to an expert in the field. In the production of tablets, it is possible to use goat colostrum or cow colostrum in granulated, unground form, which was obtained no later than 6 hours after birth. In both cases, the composition or mechanical properties of the tablet do not change, but the method of their production.

The core of a nutritional food supplement tablet containing dried colostrum granulate and filler is produced by first weighing the powdered raw materials in the required ratio and placing them in a homogenizer. The homogenizer is a mixing granulator HLSG-300. The homogenizer is closed and set to 15 rpm. The homogenization time is set to 20 minutes. After homogenization, the mixture is transferred to a stainless steel container and prepared for tableting. Tableting takes place on an automatic machine type ZP29 or ZW-31 at a pressure of 60 kN. The core of the tablet is pressed at a pressure of 60 kN, a value chosen so as to achieve sufficient force to create a firm and stable tablet and at the same time so as not to destroy the protein component of the colostrum. The tablet core is pressed with powdered goat or cow colostrum, filler, anti-caking and glidant. The filler can be selected from the group of substances containing psyllium, inulin and microcrystalline cellulose or a mixture thereof. The anti-caking agent is magnesium stearate and the sliding agent is Aerosil. After pressing the tablets, these tablets are provided with an enteric coating.

The enteric coating of the tablet is prepared by dissolving the EASCOL™-EABL55 enteric coating system in water. In this way, an aqueous solution with a concentration of 15% by volume of the enteric coating substance, Eudragit LI00-55, is prepared. Subsequently, the solution is applied in a BG-80 coating machine from the Jiangnan company by spraying through nozzles onto the pressed tablet core. The volumetric flow rate of the water solution is 0.12 1/min for 120 min. At the end of the process, a stable tablet is obtained consisting of a tablet core with powdered colostrum, a filler, an anti-caking and sliding agent, and an enteric coating.

-6 CZ 309222 B6

Component Content [wt%] Colostrum 20 20 25 25 30 30 Psyllium 73 0 0 65 0 34 Inulin 0 37.1 68.1 5 0 0 Microcrystalline cellulose 0 35 0 0 59.1 30 Magnesium stearate 1 0.9 0.9 0 0.9 1 Aerosil 2 2 2 0 2 1 Eudragit LI00-55 4 5 5 5 3 4

Table 1. Composition of nutritional supplement tablets with colostrum and enteric coating. The contents of individual components are given relative to 100% of the weight of the composition.

Table 1 shows illustrative examples of the contents of the individual components in a tablet of the nutritional food supplement according to the present invention. The tablet can be, for example, 1 g, 500 mg, etc., while maintaining the stated contents. Tablets can be produced in various shapes and sizes. Tablets weighing 1 g contain a maximum of 3% by weight. excipients. The content of excipients does not change in tablets weighing 1 g and in tablets weighing 0.5 g, which preserves the correct mechanical properties of the tablet. In the given exemplary compositions, the term colostrum refers to cow or goat colostrum.

Table 2 shows the contents of the immunoglobulin fraction in goat colostrum taken from the female at 6, 12 and 24 h after the birth of the kid. The content of the immunoglobulin fraction was tested using the so-called zinc sulfate turbidity test, in which immunoglobulins from the colostrum sample are selectively precipitated with a solution of zinc sulfate (ZnSO4). The content is expressed in zinc sulfate units (ZSJ), which are the standard units used in the analysis of immunoglobulins in blood. When converting ZSJ to % wt. Ig fraction, it is necessary to take into account the dry matter content in the tested sample of goat colostrum, in this case 22% by weight. relative to the weight of the colostrum, and the dry matter dilution factor when reconstituting the sample when performing the test itself, in this case 9 parts solvent to 1 part dry matter. Factor for conversion of Ig fraction content in ZSJ units to content in % wt. so it is 2.2. From the data below, it can be deduced that only the sample of goat colostrum taken 6 h after birth contains more than 8% by weight. Ig fraction relative to colostrum weight, and that goat colostrum samples taken up to 12 and 24 h after parturition no longer reach a sufficient level of Ig fraction for use in the presented nutritional food supplement.

Collection time after delivery fh] 6 12 24 Ig fraction content [ZSJ] 6.0 3.1 1.4 Content of Ig fraction f% wt.] 13.2 6.8 3.1

Table 2. Content of the immunoglobulin fraction in goat colostrum with different collection times. The content of the Ig fraction is given in wt.%. relative to the weight of the colostrum.

Industrial applicability

A nutritional supplement containing granulated colostrum with supporting effects for the immune system with an enteric coating finds industrial use in the food industry as a dietary supplement for children, adults or animals.

Claims (11)

PATENT CLAIMS 1. Nutritional supplement comprising an enteric coating and a core containing colostrum and a filler, wherein the nutritional food supplement contains colostrum in an amount from 10% by mass to 30% by mass, filler in an amount from 60% by mass to 80% by mass, and an enteric coating in an amount from 2% mass to 6% mass, relative to 100% of the weight of the nutritional food supplement, the colostrum being goat and/or cow colostrum, characterized by the fact that the colostrum is in granulated, unground form and the minimum content of the immunoglobulin fraction in the colostrum is 21% mass, relative to the weight of colostrum. 2. Nutritional food supplement according to claim 1, characterized in that the filler is psyllium, inulin, microcrystalline cellulose or a mixture thereof. 3. Nutritional food supplement according to any one of the preceding claims, characterized in that the enteric coating is a poly(methacrylic acid-£o-ethyl acrylate) copolymer with a ratio of free carboxyl groups to ester groups of 1:1. 4. Nutritional food supplement according to any one of the preceding claims, characterized in that it further includes an anti-caking agent in an amount from 0% mass to 1% mass, and a sliding agent in an amount from 0% mass to 2% mass, relative to 100 % by weight of the composition. 5. Nutritional food supplement according to claim 4, characterized in that the anti-caking agent is magnesium stearate, and the sliding agent is aerosil. 6. Nutritional food supplement according to any one of the preceding claims, characterized in that it is in the form of a tablet, capsule, lozenge, dragee or suppository. 7. A method of producing a nutritional food supplement according to any one of the preceding claims, characterized in that it includes the following steps: a. removal of colostrum from a female animal no later than 6 h after giving birth; b. cooling the colostrum to at least 4 °C and freezing the colostrum to at least -25 °C; c. drying colostrum by lyophilization or spray drying; d. sifting lyophilized colostrum through a sieve to form granulate; e. homogenization of colostrum granulate with filler; f. pressing the homogenized mixture into the core; and g. application of an aqueous solution of an enteric coating. 8. The method according to claim 7, characterized in that the removal of colostrum from the female animal is carried out no later than 2 hours after giving birth. 9. The method according to claim 7 or 8, characterized in that the sieving of the lyophilized colostrum is carried out through sieves to form granules with a particle size of 1 to 3 mm, the homogenization of the colostrum granulate with the filler is carried out for 20 minutes at 15 rpm, pressing of the homogenized mixture into the core is carried out with a force of 60 kN, and the application of the enteric coating is carried out by injection in a 15% by volume aqueous solution at a volume flow rate of 0.12 1/min. for 120 minutes. 10. The method according to any one of claims 7 to 9, characterized in that the homogenization of the colostrum granulate with the filler further includes the addition of an anti-caking and sliding agent according to claim 6 or 7. 11. The method according to any one of claims 7 to 10, characterized in that the step of removing and cooling the colostrum to 4°C is followed by the step of removing casein and lipids from the colostrum by means of membrane filtration.